Literature DB >> 22426576

Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Anne Moskowitz1, Ronald M Hansen, Susan E Eklund, Anne B Fulton.   

Abstract

The antiepileptic drug vigabatrin is known to cause retinal and visual dysfunction, particularly visual field defects, in some patients. Electroretinography (ERG) is used in an attempt to identify adverse effects of vigabatrin (VGB) in patients who are not candidates for conventional perimetry. We report data from 114 pediatric patients taking VGB referred for clinical evaluation; median age at test was 22.9 (2.4 to 266.1) months, and median duration of VGB use was 9.7 (0.3 to 140.7) months. Twenty-seven of them were tested longitudinally (3 to 12 ERG tests). ERG responses to full-field stimuli were recorded in scotopic and photopic conditions, and results were compared to responses from healthy control subjects. We found that abnormalities of photoreceptor and post-receptor ERG responses are frequent in these young patients. The most frequently abnormal scotopic parameter was post-receptor sensitivity, log σ, derived from the b-wave stimulus-response function; the most frequently abnormal photopic parameter was the implicit time of the OFF response (d-wave) to a long (150 ms) flash. Abnormal 30-Hz flicker response amplitude, previously reported to be a predictor of visual field loss, occurred infrequently. For the group as a whole, none of the ERG parameters changed significantly with increasing duration of VGB use. Four of the 27 patients tested longitudinally showed systematic worsening of log σ with duration of VGB use. In a subset of patients who underwent perimetry (N = 39), there was no significant association of any ERG parameter with visual field defects. We cannot determine whether the ERG abnormalities we found were due solely to the effects of VGB. We caution against over-reliance on the ERG to monitor pediatric patients for VGB toxicity and recommend further development of a reliable test of peripheral vision to supplant ERG testing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426576     DOI: 10.1007/s10633-012-9320-7

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  56 in total

1.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

2.  On-bipolar cells and depolarising third-order neurons as the origin of the ERG-b-wave in the RCS rat.

Authors:  K Wurziger; T Lichtenberger; R Hanitzsch
Journal:  Vision Res       Date:  2001-04       Impact factor: 1.886

Review 3.  Amplification and kinetics of the activation steps in phototransduction.

Authors:  E N Pugh; T D Lamb
Journal:  Biochim Biophys Acta       Date:  1993-03-01

4.  Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors.

Authors:  P J Schechter; Y Tranier; M J Jung; P Böhlen
Journal:  Eur J Pharmacol       Date:  1977-10-15       Impact factor: 4.432

5.  Visual field constriction and electrophysiological changes associated with vigabatrin.

Authors:  Dorothea Besch; Anne Kurtenbach; Eckart Apfelstedt-Sylla; Bettina Sadowski; Dieter Dennig; Christiane Asenbauer; Eberhart Zrenner; Ulrich Schiefer
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

6.  Visual field and electrophysiological abnormalities due to vigabatrin.

Authors:  Kors van der Torren; Hellen S Graniewski-Wijnands; B C P Polak
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

7.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

8.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

9.  Augmented rod bipolar cell function in partial receptor loss: an ERG study in P23H rhodopsin transgenic and aging normal rats.

Authors:  T S Aleman; M M LaVail; R Montemayor; G Ying; M M Maguire; A M Laties; S G Jacobson; A V Cideciyan
Journal:  Vision Res       Date:  2001-09       Impact factor: 1.886

10.  Longitudinal changes in photopic OPs occurring with vigabatrin treatment.

Authors:  Sharon Morong; Carol A Westall; Rita Nobile; J Raymond Buncic; William J Logan; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

View more
  10 in total

1.  Limiting Retinal Toxicity of Vigabatrin in Children With Infantile Spasms.

Authors:  Prakash Kotagal
Journal:  Epilepsy Curr       Date:  2015 Nov-Dec       Impact factor: 7.500

2.  Progressive retinal degeneration in a girl with Knobloch syndrome who presented with signs of ocular albinism.

Authors:  Libe Gradstein; Ronald M Hansen; Gerald F Cox; Pablo Altschwager; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2017-01-31       Impact factor: 2.379

3.  Epilepsy: Update to guidelines on treatment of infantile spasms.

Authors:  Raili Riikonen
Journal:  Nat Rev Neurol       Date:  2012-08-07       Impact factor: 42.937

4.  Vigabatrin can enhance electroretinographic responses in pigmented and albino rats.

Authors:  James D Akula; Emily R Noonan; Alessia Di Nardo; Tara L Favazza; Nan Zhang; Mustafa Sahin; Ronald M Hansen; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2015-03-12       Impact factor: 2.379

5.  Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.

Authors:  Rachel Dragas; Carol Westall; Tom Wright
Journal:  Doc Ophthalmol       Date:  2014-07-10       Impact factor: 2.379

6.  Vigabatrin-induced retinal toxicity is partially mediated by signaling in rod and cone photoreceptors.

Authors:  Jin Yang; Matthew C Naumann; Yi-Ting Tsai; Joaquin Tosi; Deniz Erol; Chyuan-Sheng Lin; Richard J Davis; Stephen H Tsang
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

7.  Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.

Authors:  Carol A Westall; Tom Wright; Filomeno Cortese; Ananthavalli Kumarappah; O Carter Snead; Joseph R Buncic
Journal:  Neurology       Date:  2014-11-07       Impact factor: 9.910

8.  Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice.

Authors:  Kore Chan; Mrinalini Hoon; Bikash R Pattnaik; James N Ver Hoeve; Brad Wahlgren; Shawna Gloe; Jeremy Williams; Brenna Wetherbee; Julie A Kiland; Kara R Vogel; Erwin Jansen; Gajja Salomons; Dana Walters; Jean-Baptiste Roullet; K Michael Gibson; Gillian J McLellan
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

9.  Clinical trial of vigabatrin as adjunctive therapy in children with refractory epilepsy.

Authors:  Mohammad-Mahdi Taghdiri; Mahmoud-Reza Ashrafi; Mohammad-Kazem Bakhshandeh-Bali; Seyedeh-Mohadeseh Taheri-Otaghsara; Mohammad-Mahdi Nasehi
Journal:  Iran J Pediatr       Date:  2013-12       Impact factor: 0.364

10.  ISCEV extended protocol for the photopic On-Off ERG.

Authors:  Maja Sustar; Graham E Holder; Jan Kremers; Claire S Barnes; Bo Lei; Naheed W Khan; Anthony G Robson
Journal:  Doc Ophthalmol       Date:  2018-06-22       Impact factor: 2.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.